CHOLESTOSOMES

Therasyn Sensors, Inc.

Application Filed: 2018-10-03
Trademark Application Details
Trademark Logo CHOLESTOSOMES

Mark For: CHOLESTOSOMES™ trademark registration is intended to cover the categories of pharmaceutical preparations for Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung disease, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), and ankylosing spondylitis; vaccines and vaccinations to prevent or treat infectious diseases and cancer; drug delivery agents in the form of capsules made of lipids, containing and facilitating the delivery of pharmaceuticals for the treatment of Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung disease, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), ankylosing spondylitis; vaccines and vaccinations to prevent or treat infectious diseases and cancer; drug delivery agents in the form of capsules made of cholesteryl ester, containing and facilitating the delivery of pharmaceuticals for use in the treatment of Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung disease, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non- alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), and ankylosing spondylitis; and vaccines and vaccinations to prevent or treat infectious diseases and cancer. [all]

Status

2021-06-03 UTC
LIVE APPLICATION Under Examination
The trademark application has been accepted by the Office (has met the minimum filing requirements) and that this application has been assigned to an examiner.


Research OneLook Acronym Finder
Serial Number88141769
Mark Literal ElementsCHOLESTOSOMES
Mark Drawing Type4 - STANDARD CHARACTER MARK
Mark TypeTRADEMARK
RegisterPRINCIPAL
Current LocationINTENT TO USE SECTION 2019-11-05
Basis1(b)
Class StatusACTIVE
Primary US Classes
  • 006: Chemicals and Chemical Compositions
  • 018: Medicines and Pharmaceutical Preparations
  • 044: Dental, Medical and Surgical Appliances
  • 046: Foods and Ingredients of Foods
  • 051: Cosmetics and Toilet Preparations
  • 052: Detergents and Soaps
Primary International Class
  • 005 - Primary Class
  • (Pharmaceuticals) Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
Filed UseNo
Current UseNo
Intent To UseYes
Filed ITUYes
44D FiledNo
44E CurrentNo
66A CurrentNo
Current BasisNo
No BasisNo
Attorney NameR. Neil Sudol
Attorney Docket NumberF29-020
Law Office AssignedM20
Employee NameNEWKIRK, MERIDITH E.

Timeline

2018-10-03Application Filed
2019-09-10Published
2019-09-10Published for Opposition
2019-11-05Location: INTENT TO USE SECTION
2019-11-05Status: Live/Pending
2019-11-05Transaction Date
2021-04-26Status: A third request for extension of time to file a Statement of Use has been granted.

Trademark Parties (Applicants & Owners)

Party: Therasyn Sensors, Inc.
Address100 Crosby Blvd Buffalo, NEW YORK UNITED STATES 142263246
Legal Entity TypeCorporation
Legal Entity StateNEW YORK

Documents

DrawingJPEG2018-10-03
TEAS RF New ApplicationMULTI2018-10-03
Notation to FileXML2019-01-22
Offc Action OutgoingXML2019-01-22
XSearch Search SummaryXML2019-01-22
Response to Office ActionAPPLICATION/XML2019-07-18
Amendment and Mail Process CompleteAPPLICATION/XML,IMAGE/JPEG2019-07-30
TRAM Snapshot of App at Pub for OppostnAPPLICATION/XML,IMAGE/JPEG2019-08-06
Notice of PublicationXML2019-08-21
Notification Of Notice of PublicationXML2019-08-21
OG Publication ConfirmationAPPLICATION/XML2019-09-10
Notice of AllowanceAPPLICATION/XML2019-11-05
Extension of Time to File SOUAPPLICATION/XML2020-04-17
ITU Extension ApprovalXML2020-04-21
ITU Unit ActionAPPLICATION/XML,IMAGE/JPEG2020-04-21
Extension of Time to File SOUAPPLICATION/XML2020-10-29
ITU Extension ApprovalAPPLICATION/XML2020-10-31
ITU Unit ActionAPPLICATION/XML,IMAGE/JPEG2020-11-02
Extension of Time to File SOUAPPLICATION/XML2021-04-26
ITU Extension ApprovalAPPLICATION/XML2021-04-28
ITU Unit ActionAPPLICATION/XML,IMAGE/JPEG2021-04-28

Attorney of Record

R. NEIL SUDOL
COSUD INTELLECTUAL PROPERTY SOLUTIONS, P
714 COLORADO AVENUE
BRIDGEPORT, CT 06605-1601

Good, Services, and Codes


IC 005. US 006 018 044 046 051 052. G & S: Pharmaceutical preparations for Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung disease, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), and ankylosing spondylitis; vaccines and vaccinations to prevent or treat infectious diseases and cancer; drug delivery agents in the form of capsules made of lipids, containing and facilitating the delivery of pharmaceuticals for the treatment of Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung disease, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), ankylosing spondylitis; vaccines and vaccinations to prevent or treat infectious diseases and cancer; drug delivery agents in the form of capsules made of cholesteryl ester, containing and facilitating the delivery of pharmaceuticals for use in the treatment of Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung disease, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non- alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), and ankylosing spondylitis; and vaccines and vaccinations to prevent or treat infectious diseases and cancer

International Codes:5
U.S. Codes:006,018,044,046,051,052
Type CodeType
GS0051Pharmaceutical preparations for Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung disease, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), and ankylosing spondylitis; vaccines and vaccinations to prevent or treat infectious diseases and cancer; drug delivery agents in the form of capsules made of lipids, containing and facilitating the delivery of pharmaceuticals for the treatment of Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung disease, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), ankylosing spondylitis; vaccines and vaccinations to prevent or treat infectious diseases and cancer; drug delivery agents in the form of capsules made of cholesteryl ester, containing and facilitating the delivery of pharmaceuticals for use in the treatment of Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung disease, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non- alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), and ankylosing spondylitis; and vaccines and vaccinations to prevent or treat infectious diseases and cancer

Trademark Filing History

DescriptionDateProceeding Number
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED2021-04-28
TEAS EXTENSION RECEIVED2021-04-26
EXTENSION 3 GRANTED2021-04-2698765
EXTENSION 3 FILED2021-04-2698765
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED2020-10-31
TEAS EXTENSION RECEIVED2020-10-29
EXTENSION 2 GRANTED2020-10-2998765
EXTENSION 2 FILED2020-10-2998765
ASSIGNED TO EXAMINER2020-05-0167512
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED2020-04-21
TEAS EXTENSION RECEIVED2020-04-17
EXTENSION 1 GRANTED2020-04-1798765
EXTENSION 1 FILED2020-04-1798765
NOA E-MAILED - SOU REQUIRED FROM APPLICANT2019-11-05
PUBLISHED FOR OPPOSITION2019-09-10
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED2019-09-10
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED2019-08-21
APPROVED FOR PUB - PRINCIPAL REGISTER2019-08-04
TEAS/EMAIL CORRESPONDENCE ENTERED2019-07-2968552
CORRESPONDENCE RECEIVED IN LAW OFFICE2019-07-2968552
ASSIGNED TO LIE2019-07-2368552
TEAS RESPONSE TO OFFICE ACTION RECEIVED2019-07-18
NOTIFICATION OF NON-FINAL ACTION E-MAILED2019-01-226325
NON-FINAL ACTION WRITTEN2019-01-2292453
NON-FINAL ACTION E-MAILED2019-01-226325
ASSIGNED TO EXAMINER2019-01-1592453
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM2018-10-12
NEW APPLICATION ENTERED IN TRAM2018-10-06

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed